Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 455 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Papillomaviridae Clear all
Recruiting Not applicable Interventional

Provider Recommendation and HPV Vaccination

NCT05365048
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Local Tailoring implementation strategy, Prescribed Strategy
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 70 Years
Enrollment
301,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

NCT02231879
View directory record Official record
Conditions
Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
Interventions
Plerixafor, G-CSF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 9, 2026, 1:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of HPV Infection in Men: The HIM Study

NCT00786760
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Cohort: 3000 men examined every 6 months for 4 years., Pilot study: 150 men examined every 6 months for 4 years.
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
1,431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Reminders to Complete HPV Series

NCT01731496
View directory record Official record
Conditions
Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
Interventions
Telephone reminder, Text Message reminder
Other
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 21 Years
Enrollment
749 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 9, 2026, 1:50 AM EDT
Not listed Not applicable Interventional

Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise

NCT03604393
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Practice facilitation
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

NCT01302834
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, cisplatin, IMRT
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
183
States / cities
Anchorage, Alaska • Auburn, California • Burbank, California + 152 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 9, 2026, 1:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187
View directory record Official record
Conditions
Genital Warts, Perianal Warts
Interventions
NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Fountain Valley, California • Lomita, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

NCT03726151
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
17,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Canoga Park, California • Pacoima, California • San Fernando, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 9, 2026, 1:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

High-Risk HPV Infections in Women Aged 25 to 65

NCT00461877
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 9, 2026, 1:50 AM EDT
Terminated Phase 3 Interventional

Cold Atmospheric Plasma Device Extension Study

NCT05937672
View directory record Official record
Conditions
Verruca Vulgaris, Molluscum Contagiosum
Interventions
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
4 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

NCT04572100
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy, Paclitaxel, Carboplatin
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 9, 2026, 1:50 AM EDT
Not listed Not applicable Interventional

Microwave Treatment of Common and Plantar Warts

NCT05371834
View directory record Official record
Conditions
Warts
Interventions
Microwave Treatment (Swift System), Cryotherapy
Device
Lead sponsor
Blackwell Device Consulting
Industry
Eligibility
18 Years to 64 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Miami, Florida • Palm Harbor, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028
View directory record Official record
Conditions
Common Wart
Interventions
A-101 Topical Solution, A-101 Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series

NCT01343485
View directory record Official record
Conditions
GARDASIL Vaccination
Interventions
Computer reminder system
Behavioral
Lead sponsor
Planned Parenthood Federation of America
Other
Eligibility
19 Years to 26 Years · Female only
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Glendale, Arizona • Arvada, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preparedness Study - HPV Vaccine

NCT01489527
View directory record Official record
Conditions
Sexual Transmission of Infection
Interventions
Gardasil Vaccine, Placebo
Biological · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

NCT00703196
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
folic acid, placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

NCT00572832
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 23 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

NCT02499120
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
palbociclib, Cetuximab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SMS HPV Vaccine Reminders

NCT05151367
View directory record Official record
Conditions
Human Papillomavirus Vaccination
Interventions
Text message reminder
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 9, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

NCT00231413
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2, HPV-16/18/31/45 L1 AS04 Formulation 3, HPV-16/18/31/45 L1 AS04 Formulation 4, HPV-16/18/31/45 L1 AS04 Formulation 5, HPV-16/18/31/45 L1 AS04 Formulation 6
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Aurora, Colorado • Golden, Colorado • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 9, 2026, 1:50 AM EDT